Shares of Sol-Gel Technologies (SLGL) were in the spotlight on Friday morning after the company’s first-quarter (Q1) revenue dipped below Wall Street expectations, and losses came in ...

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland ...

Under the terms of the agreement, Sol-Gel will receive a total of $16 million in two installments: $10 million in the second quarter of 2025 and $6 million in the fourth quarter of 2025 ...

Sol-Gel Technologies reports increased Q1 revenue and expenses, with a net loss of $8.8 million compared to $6.3 million in 2024. Sol-Gel Technologies, Ltd., a clinical-stage dermatology company ...

NESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a ...

The sol-gel process is a widely used method for synthesizing nanoparticles with precise control over size, shape, and composition. This method converts a liquid precursor, or "sol," into a solid gel ...

The sol-gel synthesis process begins with the preparation of a sol, where metal or metalloid precursors are dissolved in a solvent. These precursors undergo hydrolysis and polymerization reactions, ...

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Total revenue in the first quarter was $1 ...

About Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical ...